New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:08 EDTABT, ALR, DHR, RHHBYAlere CEO departure sharpens focus on potential acquisition, says JMP Securities
After the CEO of Alere, Ron Zwanziger, resigned, JMP Securities thinks the resignation "brings the notion of Alere's potential acquisition front and center." The firm sees Alere as "a natural fit" for Roche (RHHBY), Abbott (ABT), or Danaher (DHR).
News For ALR;RHHBY;DHR;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 29, 2015
09:27 EDTRHHBYRoche management to meet with Jefferies
Subscribe for More Information
May 28, 2015
09:02 EDTRHHBYSeattle Genetics says data from ADC programs to be presented at ASCO
Seattle Genetics (SGEN) announced that data from multiple proprietary and collaborator antibody-drug conjugate programs will be highlighted in more than 10 sessions at the American Society of Clinical Oncology 2015 Annual Meeting being held May 29 to June 2, 2015 in Chicago, IL. Presentations will feature data from several corporate and investigator-sponsored trials with ADCETRIS, including additional analyses from the phase 3 AETHERA clinical trial and updated data in frontline diffuse large B-cell lymphoma. In addition, the company’s ADC collaborators, including Genentech (RHHBY), AbbVie (ABBV), Genmab and Agensys, will report data from clinical programs using Seattle Genetics’ ADC technology. Seattle Genetics will also present preclinical data from its novel SEA-CD40 immuno-oncology candidate currently being evaluated in a phase 1 clinical trial. Seattle Genetics is evaluating its ADC technology broadly through ADCETRIS, proprietary pipeline and collaborator programs. The company is leading the field in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. In addition, Seattle Genetics is building on expertise in empowered, targeted approaches for the treatment of cancer in advancing its proprietary sugar-engineered antibody technology, a novel technology designed to increase the potency of monoclonal antibodies through glycoengineering which may lead to an improved antitumor immune response.
08:55 EDTRHHBYXenon Pharmaceuticals sees IND for phase 1 trial of XEN801 in mid-2015
Xenon Pharmaceuticals (XENE) announced that Dr. Simon Pimstone, Xenon's President and CEO, will present a business update, including progress toward milestones, at the Jefferies Global Healthcare Conference on Tuesday, June 2. Xenon's partner Teva Pharmaceutical (TEVA) is conducting a randomized, double-blind, placebo-controlled Phase 2b clinical trial for TV-45070 in osteoarthritis. Results from the trial are now expected late in the second quarter or early in the third quarter of 2015. Xenon's partner Genentech, a member of the Roche Group (RHHBY), is currently conducting a Phase 1 clinical trial for GDC-0276, which is expected to complete patient enrollment in the second half of 2015. Xenon expects to file an investigational new drug equivalent application to initiate a Phase 1 clinical trial of XEN801, a stearoyl Co-A desaturase or SCD1 inhibitor for treatment of acne, in mid-2015. If supported by positive data from the Phase 1 trial, Xenon plans to initiate a proof-of-concept Phase 2 clinical trial in the second half of 2015. Xenon expects to file an investigational new drug application for Xenon's Nav1.6 sodium channel inhibitor for Dravet Syndrome in 2016.
08:42 EDTRHHBYJPMorgan life sciences analyst holds an analyst/industry conference call
Subscribe for More Information
08:21 EDTRHHBYAmgen could be hurt by Roche deal, says RBC Capital
Subscribe for More Information
May 27, 2015
10:01 EDTABTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abbott (ABT) initiated with a Buy at Evercore ISI... Aldeyra (ALDX) initiated with a Buy at Janney Capital... Black Stone Minerals (BSM) initiated with a Neutral at Credit Suisse... Boston Scientific (BSX) initiated with a Buy at Evercore ISI... Cidara Therapeutics (CDTX) initiated with a Buy at BTIG... Coach (COH) initiated with an Underweight at BB&T... Diplomat Pharmacy (DPLO) initiated with an Outperform at Raymond James... EPIRUS (EPRS) initiated with a Buy at BTIG... Enviva (EVA) initiated with a Buy at Citigroup... General Finance Corp (GFN) initiated with an Outperform at Oppenheimer... Hortonworks (HDP) initiated with an Outperform at Oppenheimer... Jarden (JAH) initiated with a Buy at UBS... Kate Spade (KATE) initiated with a Buy at BB&T... Medtronic (MDT) initiated with a Hold at Evercore ISI... MoneyGram (MGI) initiated with a Neutral at Goldman... Opexa Therapeutics (OPXA) initiated with a Buy at Maxim... Paratek Pharmaceuticals (PRTK) initiated with a Buy at BTIG... Progenics (PGNX) initiated with a Buy at BTIG... Rite Aid (RAD) initiated with a Buy at Mizuho... St. Jude Medical (STJ) initiated with a Buy at Evercore ISI... Starwood Waypoint (SWAY) initiated with an Outperform at Wells Fargo... Talen Energy (TLN) initiated with a Hold at Deutsche Bank... Ulta Salon (ULTA) initiated with a Buy at Buckingham... Vipshop (VIPS) initiated with a Buy at Stifel... Virtu Financial (VIRT) initiated with a Neutral at Citigroup... Vista Outdoor (VSTO) initiated with a Buy at Wunderlich... ZELTIQ (ZLTQ) initiated with a Buy at Northcoast... eBay (EBAY) initiated with a Buy at Topeka.
08:33 EDTRHHBYHalozyme and Ventana enter into global agreement to develop companion diagnostic
Halozyme (HALO) and Ventana Medical Systems, a member of the Roche (RHHBY), announced a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20. The Ventana assay will be used to identify high levels of hyaluronan. HA is a glycosaminoglycan that can accumulate around cancer cells. Halozyme has announced plans for rollout of a global phase 3 clinical study in 2016 targeting metastatic pancreatic cancer patients with high HA levels using its PEGPH20 in combination with ABRAXANE and gemcitabine. Under the agreement, Ventana will develop an in vitro diagnostic, under design control, using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval in the United States, Europe and other countries. The financial terms of the agreement were not disclosed.
07:42 EDTABTAbbott initiated with a Buy at Evercore ISI
Target $54.
May 26, 2015
07:30 EDTALRAlere should continue to be accumulated at current levels, says Canaccord
Canaccord recommended investors continue to accumulate shares of Alere given expectations for multiple expansion, management execution on core initiatives, and a deep commitment to quality. Canaccord reiterated its Buy rating and raised its price target to $60 from $56 on Alere shares.
06:16 EDTABTAbbott to start selling G.M.O-free Similac Advance formula, NY Times reports
Subscribe for More Information
May 22, 2015
10:52 EDTRHHBYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
07:40 EDTDHRDanaher price target raised to $94 from $80 at JPMorgan
Subscribe for More Information
May 21, 2015
07:37 EDTRHHBY, ABTPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 19, 2015
08:02 EDTABTAbbott announces CE Mark for new advancement of Absorb stent system
Subscribe for More Information
May 18, 2015
16:07 EDTRHHBYIllumina files new patent infringement suit against Roche unit
Subscribe for More Information
11:23 EDTABTFitch downgrades Abbott's L-T IDR to A; outlook revised to stable
Subscribe for More Information
10:01 EDTRHHBYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: A10 Networks (ATEN) upgraded to Overweight from Sector Weight at Pacific Crest... Cal-Maine Foods (CALM) upgraded to Overweight from Equal Weight at Stephens... ChemoCentryx (CCXI) upgraded to Overweight from Neutral at JPMorgan... Cheniere Energy Partners LP (CQP) upgraded to Buy from Neutral at Goldman... Chicago Bridge & Iron (CBI) upgraded to Neutral from Sell at Goldman... Continental Resources (CLR) upgraded to Buy from Neutral at Goldman... Ctrip.com (CTRP) upgraded to Overweight from Neutral at JPMorgan... Emerge Energy (EMES) upgraded to Buy from Neutral at Goldman... FEMSA (FMX) upgraded to Overweight from Equal Weight at Morgan Stanley... GoPro (GPRO) upgraded to Perform from Underperform at Oppenheimer... Holly Energy (HEP) upgraded to Buy from Neutral at Goldman... JP Energy (JPEP) upgraded on better visibility on volumes at RBC Capital... Laredo Petroleum (LPI) upgraded to Neutral from Sell at Goldman... Malvern Bancorp (MLVF) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Goldman... Norsk Hydro (NHYDY) upgraded to Overweight from Neutral at JPMorgan... Owens-Illinois (OI) upgraded to Neutral from Underperform at BofA/Merrill... Penn National (PENN) upgraded to Buy from Neutral at Goldman... Roche (RHHBY) upgraded to Buy from Neutral at UBS... Schnitzer Steel (SCHN) upgraded on stabilizing headwinds at KeyBanc... Seventy Seven Energy (SSE) upgraded to Buy from Hold at Jefferies... Toll Brothers (TOL) upgraded to Neutral from Underperform at Sterne Agee CRT... United Therapeutics (UTHR) upgraded to Buy from Neutral at BTIG... Volvo (VOLVY) upgraded to Neutral from Underweight at JPMorgan... Zayo Group (ZAYO) upgraded to Buy from Neutral at Goldman.
09:23 EDTRHHBYRoche upgraded to Buy from Neutral at UBS
Subscribe for More Information
07:19 EDTDHRElectric Products Group to hold a conference
EPG 2015 is being held in Longboat Key, Florida on May 18-20 with webcasted company presentations to begin on May 18 at 7:30 am; not all company presentations may be webcasted. Webcast Link
May 15, 2015
16:21 EDTDHRStocks end week little changed as data, deals offset bond yield jumps
Stocks ended the week little changed as a number of M&A deals and a few relatively strong economic data points offset worries about rising bond yields. MACRO NEWS: U.S. weekly jobless claims came in better than expected and reached the lowest four-week average level in 15 years... In Europe, the combined GDP of the 19 eurozone countries grew 0.4% in the first quarter, which was a bit weaker than the 0.5% consensus growth forecast but a pickup from the 0.3% growth pace of the final quarter of last year. Of note, all four of the euro zone's largest economies recorded growth in the same quarter for the first time since the first half of 2010... The People's Bank of China reduced its one year interest rate by 0.25%, marking the third time in the last six months that the central bank has cut benchmark rates... Bond yields surged in many of the world's largest economies, raising worries about inflation and putting pressure on stocks in the beginning of the week. COMPANY NEWS: There was a significant amount of M&A activity again this week, with the headliner being Verizon's (VZ) deal to acquire AOL (AOL) for $50 per share in a transaction valued at $4.4B. Danaher (DHR) agreed to buy purification technologies supplier Pall Corporation (PLL) for $127.20 per share in cash. Danaher also announced that it plans to split itself into two publicly traded companies. Energy infrastructure company Williams (WMB) announced a simplification deal to buy its affiliate Williams Partners (WPZ) for $13.9B in an all-stock transaction. Energy exploration company Noble Energy (NBL) agreed to acquire Rosetta Resources (ROSE) in an all-stock deal. Noble is buying Rosetta for $2.1B in stock plus the assumption of Rosetta's net debt of $1.8B... Alibaba (BABA) acquired a 9.3% stake in Zulily (ZU), an e-commerce retailer geared toward women. A person familiar with the matter reportedly told the Wall Street Journal that the Chinese e-commerce giant is not pursuing an outright acquisition of the U.S. company, however... Shares of Netflix (NFLX) jumped Friday and hit a new all-time high after Bloomberg reported that the company is in talks with Wasu Media, a Chinese media company backed by Alibaba Executive Chairman Jack Ma, about forming a partnership to bring its content to China... Nelson Peltz's Trian Fund Management lost its proxy fight with DuPont (DD) as Trian did not succeed in getting its nominees elected to the DuPont board. INDEXES: For the week, the Dow rose 0.45% to 18,272.56, the Nasdaq gained 0.89% to 5,048.29, and the S&P 500 climbed 0.31% to 2,122.73.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use